产前糖皮质激素应用时机及与早产原因的关系

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (628 KB) HTML (23 KB)
输出: BibTeX | EndNote (RIS)

摘要目的调查本院胎龄35周以下早产儿母亲产前糖皮质激素应用时机,并确定最佳给药时机及与早产原因的关系。方法回顾性分析2016年1月—2020年6月分娩的胎龄35周以下的早产儿及其母亲的临床资料,比较不同早产原因下产前地塞米松应用时机的差异,应用多因素Logistic分析产前地塞米松最佳给药时机的影响因素。结果本院胎龄＜35周的早产儿母亲产前地塞米松使用率为89.6%,其中46.4%在最佳给药时机接受产前地塞米松。不同早产原因的早产儿母亲产前地塞米松应用时机差异存在统计学意义。多因素Logistic回归分析显示,早产原因为胎膜早破的早产儿母亲接受最佳时机产前地塞米松的机会是非胎膜早破的2.22倍(OR=2.22,95% CI:1.19～4.14),而双胎妊娠孕妇接受最佳时机产前地塞米松的机会仅为单胎妊娠孕妇的0.24倍(OR=0.24,95% CI:0.09～0.63)。结论本院产前地塞米松使用率较高,但大多数是在次佳给药时机给药。胎膜早破是早产儿母亲在最佳给药时机接受产前地塞米松治疗的有利因素,而双胎妊娠是最佳给药时机的不利因素。提高准确预测早产发动的能力,有助于优化产前地塞米松的应用时机。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王慧
	曹丽芳
	张雪峰

关键词 ：早产, 产前糖皮质激素, 地塞米松, 给药时机

收稿日期: 2020-08-05

ZTFLH:	R71
	R72

通讯作者: 张雪峰(doctor1966@sina.com)

引用本文:

王慧, 曹丽芳, 张雪峰. 产前糖皮质激素应用时机及与早产原因的关系[J]. 中国生育健康杂志, 2022, 33(4): 362-365.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2022/V33/I4/362

1 Wong TTC,Tung JSZ,Lau HCQ,et al.Antenatal corticosteroids administration:are we giving them at the right time?.Arch Gynecol Obstet,2018,297:373-379.
2 Norman M,Piedvache A,Børch K,et al.Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity among very preterm infants:results from the EPICE cohort.JAMA Pediatr.2017,171:678-686.
3 Hannah DM,Taboada CD,Tressler TB,et al.Analysis of clinical diagnosis for all patients receiving antenatal betamethasone in a community hospital.J Neonatal Perinatal Med,2018,11:295-303.
4 中华医学会妇产科学分会产科学组.早产临床诊断与治疗指南.中华妇产科杂志,2014,49:481-485.
5 Committee on Obstetric Practice.Committee Opinion No.713:Antenatal corticosteroid therapy for fetal maturation.Obstet Gynecol,2017,130:e102-e109.
6 早产儿呼吸窘迫综合征流行病学调查协作组.产前糖皮质激素对早产小于胎龄儿病死率和主要并发症的影响.中华儿科杂志,2017,55:613-618.
7 Rottenstreich A,Elchalal U,Haj Yahya R,et al.Missed opportunities for optimal antenatal corticosteroid timing in medically indicated preterm births.J Matern Fetal Neonatal Med,2019,1:1-7.
8 Ridout A,Watson H,Best R,et al.Re:Antenatal corticosteroids:it's all about timing.BJOG,2018,125:506-507.
9 Frándberg J,Sandblom J,Bruschettini M,et al.Antenatal corticosteroids:a retrospective cohort study on timing,indications and neonatal outcome.Acta Obstet Gynecol Scand,2018,97:591-597.
10 Crowther CA,McKinlay CJ,Middleton P,et al.Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes.Cochrane Database Syst Rev,2015,2015:CD003935.
11 Adams TM,Kinzler WL,Chavez MR,et al.Practice patterns in the timing of antenatal corticosteroids for fetal lung maturity.J Matern Fetal Neonatal Med,2015,28:1598-1601.
12 Adams TM,Kinzler WL,Chavez MR,et al.The timing of administration of antenatal corticosteroids in women with indicated preterm birth.Am J Obstet Gynecol,2015,212:645.e1-e4.
13 Levin HI,Ananth CV,Benjamin-Boamah C,et al.Clinical indication and timing of antenatal corticosteroid administration at a singlecentre.BJOG,2016,123:409-414.
14 American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics.Practice Bulletin No.172:Premature Rupture of Membranes.Obstet Gynecol,2016,128:e165-e177.
15 American College of Obstetricians and Gynecologists.Hypertension in pregnancy.Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy.Obstet Gynecol,2013,122:1122-1131.
16 Rottenstreich A,Levin G,Kleinstern G,et al.Patterns of use and optimal timing of antenatal corticosteroids in twin compared with singleton pregnancies.Acta Obstet Gynecol Scand,2018,97:1508-1514.